Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in
microalgae-based, high-value nutrition and health products, today
announced financial results for the first quarter of fiscal year 2016,
ended June 30, 2015.
First Quarter 2016
For the first quarter of fiscal 2016
compared to the first quarter of fiscal 2015, net sales were $7,594,000
compared to $7,624,000. Gross profit was $2,924,000, with gross profit
margin of 39%, compared to gross profit of $3,059,000 and gross profit
margin of 40%. Operating loss was ($195,000) compared to an operating
loss of ($1,048,000). Net loss was ($105,000) or ($0.02) per diluted
share, compared to a net loss of ($381,000) or ($0.07) per diluted share.
Commenting on the first quarter 2016 results (changes shown vs. first
quarter 2015), Brent Bailey, Cyanotech President and CEO, noted:
“Net sales of our Nutrex packaged consumer products grew +4% versus
prior year. First quarter net sales growth of the Nutrex business, by
channel, was:
|
|
|
~ Nutrex Mainland:
|
|
|
|
+6%
|
|
|
|
~ Nutrex Hawaii:
|
|
|
|
+1%
|
|
|
|
~ Nutrex International:
|
|
|
|
+14%
|
|
|
|
|
|
|
|
|
“Due to the fact that we grow versus manufacture our raw material,
production is often impacted by seasonal weather patterns. This was the
case in the first quarter, as Nutrex net sales growth was impacted by a
20% reduction in Astaxanthin production due to less sunlight and an
unusual level of mid-day cloud cover in Kona, HI. Further, an
unfavorable customer mix, which is not expected to continue, increased
promotional spending above normal levels resulting in a 4% reduction in
Nutrex net sales.
“Several planned business-building investments also impacted our first
quarter fiscal 2016 financial performance versus first quarter fiscal
2015:
-
An increase of $498,000 in sales and marketing expense primarily to
support the expanded Costco distribution
-
Start-up costs of $170,000 related to the new extraction facility
-
Increased R&D expenses of $61,000 for clinical trials and Research
staff additions
“Major progress was made on key strategic initiatives in the first
quarter:
-
Our market shares continue to grow. BioAstin brand retail market share
of Astaxanthin in the US natural products channel was 58% (+1 pt.).
Our Nutrex brand market share of Spirulina was 49% (+4 pts.) in fiscal
2015.
-
Based on the strong results to date, we will be expanding into the
remaining 43 Costco Los Angeles region warehouses soon. At that time,
BioAstin Astaxanthin will be available in approximately 23% of
Costco’s domestic warehouses.
-
We are making Astaxanthin production process changes that are expected
to facilitate algae growth regardless of the level of sunlight and
reduce the impact of other environmental factors on our output as well
as increase capacity. Pond fill rates and harvests/month are already
improving but the full benefits of these changes are not expected to
be realized for 12-18 months.
-
As a result of a multi-year effort by our exclusive Chinese
distributor, A-Life/Samuels, we recently received the China Food and
Drug Administration (CFDA) seal, which will allow our BioAstin brand
Astaxanthin to be imported into China. We believe that BioAstin is the
first Astaxanthin brand to receive the CFDA seal.
-
The extraction plant commissioning is now complete.
“Each of these initiatives is an important element in realizing our
potential.”
Trailing 12 Months
For the trailing 12 months ended June 30,
2015 compared to the trailing 12 months ended June 30, 2014, net sales
were $33,779,000 compared to $29,397,000 an increase of 15%. Gross
profit was $14,331,000, with gross profit margin of 42.4%, compared to
gross profit of $11,670,000 and gross profit margin of 39.7%. Pretax
income was $1,083,000 compared to a pretax loss of ($1,263,000), and net
income was $252,000 or $0.05 per diluted share, compared to a net loss
of ($696,000) or ($0.13) per diluted share.
About Cyanotech — Cyanotech Corporation, a world leader in
microalgae technology, produces BioAstin® Natural Astaxanthin and
Hawaiian Spirulina Pacifica®—all natural, functional nutrients that
leverage our experience and reputation for quality, building nutritional
brands which promote health and well-being. Cyanotech's Spirulina
products offer complete nutrition, and augment energy and immune
response. They are FDA-reviewed and accepted as Generally Recognized as
Safe (GRAS) for use in food products. BioAstin's superior antioxidant
activity and ability to support and maintain a natural anti-inflammatory
response enhance skin, muscle and joint health. All Cyanotech products
are produced from microalgae grown at our 90-acre facility in Kona,
Hawaii using patented and proprietary technology. Cyanotech sells its
products direct to consumers at retail locations in the United States
and online at www.nutrex-hawaii.com
and also distributes to nutritional supplement, nutraceutical and
cosmeceutical manufacturers and marketers worldwide and is GMP-certified
by the Natural Products AssociationTM. Visit www.cyanotech.com
for more information.
“Safe Harbor” Statement under the U.S. Private Securities Litigation
Reform Act of 1995 Besides statements of present fact and historical
fact, this press release may contain forward-looking statements.
Forward-looking statements relate to the future and are subject to
inherent uncertainties, risks and changes in circumstances that are
difficult to predict. Our actual results may differ materially from
those contemplated by forward-looking statements. We caution against
relying on forward-looking statements. Important factors that could
change actual, future results include: changes in sales levels to our
largest customers, weather patterns in Hawaii, production problems,
risks associated with new products, foreign exchange fluctuations, and
availability of financing, as well as national and global political,
economic, business, competitive, market and regulatory conditions. Other
factors are more fully detailed in the Company’s annual Form 10-K
filings with the Securities and Exchange Commission.
(Financial Tables Follow: The following tables do not contain
footnotes or other information contained in the Company’s Form 10-Q for
the period ended June 30, 2015, which can be found on the Cyanotech
website (www.cyanotech.com)
under Investors>Investor Filings upon filing. As such the following
Financial Tables are provided only as a guide and other factors are more
fully detailed in the Company’s annual Form 10-K filings with the
Securities and Exchange Commission.)
|
|
|
|
|
|
|
|
|
CYANOTECH CORPORATION
|
CONDENSED CONSOLIDATED BALANCE SHEETS
|
(Dollars in thousands, except par value and number of shares)
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2015
|
|
|
|
March 31, 2015
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
$
|
1,502
|
|
|
|
$
|
2,226
|
|
Accounts receivable, net of allowance for doubtful accounts of $6 at
June 30, 2015 and $6 at March 31, 2015
|
|
|
|
3,548
|
|
|
|
|
3,258
|
|
Inventories, net
|
|
|
|
5,839
|
|
|
|
|
5,678
|
|
Deferred tax assets
|
|
|
|
315
|
|
|
|
|
315
|
|
Prepaid expenses and other current assets
|
|
|
|
401
|
|
|
|
|
317
|
|
Total current assets
|
|
|
|
11,605
|
|
|
|
|
11,794
|
|
|
|
|
|
|
|
|
|
|
|
|
Equipment and leasehold improvements, net
|
|
|
|
15,533
|
|
|
|
|
14,754
|
|
Restricted cash
|
|
|
|
328
|
|
|
|
|
486
|
|
Deferred tax assets
|
|
|
|
3,169
|
|
|
|
|
3,035
|
|
Other assets
|
|
|
|
929
|
|
|
|
|
846
|
|
Total assets
|
|
|
$
|
31,564
|
|
|
|
$
|
30,915
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
|
|
Note Payable
|
|
|
$
|
500
|
|
|
|
$
|
—
|
|
Current maturities of long-term debt
|
|
|
|
233
|
|
|
|
|
234
|
|
Customer deposits
|
|
|
|
83
|
|
|
|
|
31
|
|
Accounts payable
|
|
|
|
3,090
|
|
|
|
|
2,926
|
|
Accrued expenses
|
|
|
|
1,055
|
|
|
|
|
1,124
|
|
Total current liabilities
|
|
|
|
4,961
|
|
|
|
|
4,315
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term debt, excluding current maturities
|
|
|
|
5,053
|
|
|
|
|
5,109
|
|
Deferred rent
|
|
|
|
8
|
|
|
|
|
8
|
|
Total liabilities
|
|
|
|
10,022
|
|
|
|
|
9,432
|
|
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ equity:
|
|
|
|
|
|
|
|
|
|
|
Common stock of $0.02 par value, shares authorized 50,000,000;
5,564,799 shares issued and outstanding at June 30, 2015 and
5,564,799 at March 31, 2015
|
|
|
|
111
|
|
|
|
|
111
|
|
Additional paid-in capital
|
|
|
|
31,010
|
|
|
|
|
30,846
|
|
Accumulated deficit
|
|
|
|
(9,579
|
)
|
|
|
|
(9,474
|
)
|
Total stockholders’ equity
|
|
|
|
21,542
|
|
|
|
|
21,483
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders’ equity
|
|
|
$
|
31,564
|
|
|
|
$
|
30,915
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CYANOTECH CORPORATION
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
|
(Dollars in thousands, except per share amounts)
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30,
|
|
|
|
|
|
2015
|
|
|
|
2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET SALES
|
|
|
|
$
|
7,594
|
|
|
|
$
|
7,624
|
|
COST OF SALES
|
|
|
|
|
4,670
|
|
|
|
|
4,565
|
|
Gross Profit
|
|
|
|
|
2,924
|
|
|
|
|
3,059
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OPERATING EXPENSES:
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative
|
|
|
|
|
1,210
|
|
|
|
|
2,747
|
|
Sales and marketing
|
|
|
|
|
1,732
|
|
|
|
|
1,234
|
|
Research and development
|
|
|
|
|
177
|
|
|
|
|
116
|
|
Loss on disposal of equipment and leasehold improvements
|
|
|
|
|
—
|
|
|
|
|
10
|
|
Total operating expenses
|
|
|
|
|
3,119
|
|
|
|
|
4,107
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
|
|
(195
|
)
|
|
|
|
(1,048
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense, net
|
|
|
|
|
24
|
|
|
|
|
25
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss before income tax
|
|
|
|
|
(219
|
)
|
|
|
|
(1,073
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
INCOME TAX BENEFIT
|
|
|
|
|
(114
|
)
|
|
|
|
(692
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
NET LOSS
|
|
|
|
$
|
(105
|
)
|
|
|
$
|
(381
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
NET LOSS PER SHARE:
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
|
$
|
(0.02
|
)
|
|
|
$
|
(0.07
|
)
|
Diluted
|
|
|
|
$
|
(0.02
|
)
|
|
|
$
|
(0.07
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
SHARES USED IN CALCULATION OF NET LOSS PER SHARE:
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
|
|
5,565
|
|
|
|
|
5,488
|
|
Diluted
|
|
|
|
|
5,565
|
|
|
|
|
5,488
|
|
|
|
|
|
|
|
|
|
|
|
|
|
View source version on businesswire.com: http://www.businesswire.com/news/home/20150807005147/en/
Copyright Business Wire 2015